STAT+: BioMarin appeases an activist

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hello, everyone. Damian here with news of an averted activist challenge, biotech on late-night TV, and the latest deal in oncology’s hottest space.

BioMarin appeases an activist

Alexander Hardy, the new CEO of BioMarin Pharmaceutical, had an unenviable introduction to the job. Weeks before his first day, Elliott Management, a famed and formidable activist investor, disclosed a sizable stake in BioMarin, suggesting trouble ahead for a management team that had yet to get started.

Continue to STAT+ to read the full story…